McMillan Office’s Edwards Lifesciences EW Stock Holding History

McMillan Office’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$985K	Hold	10,890	–	–	0.11%	82
2026 Q1	$872K	Hold	10,890	–	–	0.11%	85
2025 Q4	$928K	Buy	+10,890	New	+$894K	0.11%	85

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

McMillan Office's EW Position: Q2 2026 in Review

McMillan Office held its Edwards Lifesciences (EW) position steady in Q2 2026 at 10,890 shares worth $985K. The position accounts for 0.11% of the portfolio, ranked #82.

McMillan Office first reported a position in EW in Q4 2025 and has held it in 3 quarters since. 1,328 funds tracked by Wall St. Rank hold EW as of Q2 2026.

McMillan Office held 10,890 shares of Edwards Lifesciences worth $985K as of Q2 2026.
McMillan Office left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.11% of McMillan Office's portfolio in Q2 2026, its #82 holding.
McMillan Office first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 3 quarters since.
1,328 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.